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The safety and maximum tolerated dose (MTD) of erlotinib with docetaxel/carboplatin were assessed in patients with ovarian cancer.
Chemonaive patients received intravenous docetaxel (75mgm
 2) and carboplatin (area under the curve 5) on day 1 of a 3-week
cycle, and oral erlotinib at 50 (cohort 1), 100 (cohort 2a) or 75mgday
 1 (cohort 2b) for up to six cycles. Dose-limiting toxicities
were determined in cycle 1. Forty-five patients (median age 59 years) received treatment. Dose-limiting toxicities occurred in 1/5/5
patients (cohorts 1/2a/2b). The MTD of erlotinib in this regimen was determined to be 75mgday
 1 (cohort 2b; the erlotinib dose
was escalated to 100mgday
 1 in 11 out of 19 patients from cycle 2 onwards). Neutropaenia was the predominant grade 3/4
haematological toxicity (85/100/95% respectively). Common non-haematological toxicities were diarrhoea, fatigue, nausea and rash.
There were five complete and seven partial responses in 23 evaluable patients (52% response rate). Docetaxel/carboplatin had no
measurable effect on erlotinib pharmacokinetics. In subsequent single-agent maintenance, erlotinib was given at 100–150mgday
 1,
with manageable toxicity, until tumour progression. Further investigation of erlotinib in epithelial ovarian carcinoma may be
warranted, particularly as maintenance therapy.
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In 2002, the estimated worldwide incidence of ovarian cancer was
almost 205000 with nearly 125000 women dying from this disease
(Globocan, 2002). Current treatment for advanced ovarian cancer
is cytoreductive surgery followed by six cycles of platinum-based
chemotherapy. In phase III trials, paclitaxel/carboplatin is as
effective as paclitaxel/cisplatin but is less toxic and also has quality
of life (QoL) benefits (Neijt et al, 2000; Ozols et al, 2003; du Bois
et al, 2003). However, paclitaxel/carboplatin can produce sig-
nificant haematologic and neurologic toxicity. Thus, new therapy
options are needed to improve both clinical outcome and
treatment tolerance.
Docetaxel has pharmacologic and pharmacokinetic (PK) ad-
vantages over paclitaxel. In phase II trials, docetaxel had
significant activity in platinum-resistant ovarian cancer (Kaye
et al, 1997) and in paclitaxel-resistant Mullerian cancers (Versh-
raegen et al, 2000). A phase III trial demonstrated that docetaxel/
carboplatin had similar efficacy to paclitaxel/carboplatin in
advanced ovarian cancer; response rates: 58.7 vs 59.5%; progression-
free survival (PFS): 15.0 vs 14.8 months (Vasey et al, 2004).
Docetaxel/carboplatin induced less neurotoxicity (e.g. grade X2
neurosensory toxicity: 11 vs 30%, Po0.001) and more haemato-
logic toxicity (e.g. grade 3/4 neutropaenia: 94 vs 84%, Po0.001)
but with improved QoL parameters compared with paclitaxel/
carboplatin. Thus, docetaxel/carboplatin could represent an
alternative first-line chemotherapy regimen for patients with
advanced ovarian cancer (du Bois et al, 2005), although not
currently registered for this indication.
Improved understanding of tumorigenesis has resulted in novel
antitumour agents acting on specific cellular targets being
developed. One therapeutic target is the human epidermal growth
factor receptor (EGFR) (Arteaga 2003). Increased EGFR expression
occurs in approximately 70% of ovarian tumours (Kohler et al,
1992). In some cancers, particularly ovarian, dysregulation of
EGFR is associated with poor prognosis (Nicholson et al, 2001).
Erlotinib (Tarceva
s) is a highly potent, orally active inhibitor of
the tyrosine kinase (TK) region of EGFR. The dose of erlotinib
recommended for further study (150mgday
 1) was identified in a
key phase I PK study (Hidalgo et al, 2001). Initial phase II clinical
trials demonstrated varied antitumour activity of erlotinib
monotherapy in a wide range of tumours, for example, head and
neck (Soulie `res et al, 2004), lung (Perez-Soler et al, 2004) and
colorectal cancer (Townsley et al, 2006). More recently, the
importance of tumour characteristics in predicting response to
Received 26 November 2007; revised 25 March 2008; accepted 28
March 2008; published online 27 May 2008
*Correspondence: Dr PA Vasey, Division of Medicine, University of
Queensland, Brisbane Q4029, Australia;
E-mail: pvasey@hoca.com.au
British Journal of Cancer (2008) 98, 1774–1780
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
serlotinib has been recognised (notably, mutations in the EGFR TKI
domain) (Uramoto and Mitsudomi, 2007). Erlotinib monotherapy
significantly prolonged survival of patients with chemorefractory
advanced NSCLC compared with best supportive care in a large
randomised trial (Shepherd et al, 2005).
In patients with refractory, recurrent, EGFR-positive epithelial
ovarian tumours who had failed prior taxane and/or platinum-
based chemotherapy, erlotinib monotherapy was generally well
tolerated (Gordon et al, 2005). In this phase II trial, the objective
response rate was 6% and 15 patients (44%) had stable disease.
Although this is not suggestive of significant efficacy as mono-
therapy in ovarian carcinoma, the addition of erlotinib to
chemotherapy has the potential to improve outcomes. Combining
agents with different modes of action and a limited overlap of
toxicity profiles should improve therapeutic strategies for patients
with advanced cancer. Preclinically, erlotinib with chemotherapy
showed additive or synergistic antitumour effects in human
xenograft models (e.g. Higgins et al, 2004; Ouchi et al, 2006).
The primary objectives of the present study were to determine
the safety, tolerability and maximum tolerated dose (MTD) of daily
oral erlotinib in combination with 3-week cycles of docetaxel/
carboplatin as first-line treatment for patients with epithelial
ovarian cancer, fallopian tube cancer or primary peritoneal cancer.
Other objectives included a PK analysis of erlotinib and the
cytotoxics, plus documentation of antitumour activity. Cytotoxic
doses were docetaxel (Taxotere
s,7 5 m g m
 2) and carboplatin
(Paraplatin
s, AUC 5), as this combination has proven efficacy in
patients with ovarian cancer (Vasey et al, 2004). Preliminary data
in heavily pretreated patients indicated increased myelogenous
toxicity with erlotinib (4100mgday
 1) when used in combination
with docetaxel 75mgm
 2 (Forouzesh et al, 2002), so for this trial, a
lower initial dose of erlotinib (50mgday
 1) was selected.
PATIENTS AND METHODS
Patient population
Eligible patients were women aged X18 years of age with
histologically confirmed epithelial ovarian, fallopian tube or
primary peritoneal carcinoma. Additional inclusion criteria were
as follows: International Federation of Gynecologic Oncology
(FIGO) stage III–IV disease; Eastern Cooperative Oncology Group
(ECOG) performance status (PS) 0–2; no prior exposure to
chemo- or radiotherapy; p8 weeks following surgery (debulking
surgery was not an entry requirement; however, patients not
considered operable must have had appropriate pathology on
biopsy). Key exclusion criteria included symptomatic peripheral
neuropathy; inadequate renal, hepatic, cardiopulmonary or
haematologic function; severe and/or uncontrolled comorbidity;
and prior sensitivity to docetaxel.
The study was approved by multicentre and local research ethics
committees, and was conducted according to the recommenda-
tions of the Declaration of Helsinki. All patients gave written
informed consent.
Trial objectives, design and drug treatment
The primary objective was to determine the safety, tolerability and
MTD of daily oral erlotinib in combination with docetaxel and
carboplatin in patients with advanced ovarian cancer. The
secondary objectives included to evaluate the PKs of erlotinib,
docetaxel and carboplatin when administered in combination and
to conduct a preliminary investigation of the antitumour activity
of this combination regimen.
This trial was a phase Ib, open-label, dose-escalation study.
Patients (12 planned/cohort) were enrolled sequentially into a
cohort. Toxicities during the first treatment cycle were used to
determine the tolerability of the dosage regimen for that cohort;
data were evaluated when all 12 patients had completed cycle 1.
Escalation of the erlotinib dose for the next cohort only took place
if less than 4 of 12 patients experienced a dose-limiting toxicity
(DLT). If four or more patients had DLTs, then patients were
recruited into the relevant interim cohort. The initial dose of
erlotinib was 50mgday
 1.
In cohort 1, patients were randomised to receive erlotinib in
either cycle 1 or 2, but not in cycles 2 and 1, respectively. This was
carried out to assess the effect of erlotinib on nadir neutrophil
counts in a crossover design. Thereafter, patients received
erlotininb in cycles 3–6 as usual.
Erlotinib hydrochloride (25, 100 and 150mg tablets) was
supplied by F Hoffmann-La Roche Ltd (Basel, Switzerland).
Commercially available preparations of docetaxel and carboplatin
were supplied. On day 1 of each cycle, docetaxel (Taxotere,
75mgm
 2, Sanofi-Aventis, Bridgewater, NJ, USA) was adminis-
tered as a 1-h intravenous infusion in 250ml of 0.9% saline,
immediately followed by carboplatin (Paraplatin, AUC 5, Bristol-
Myers Squibb, New York, NY, USA) as a 1-h intravenous infusion
in 500ml of 5% glucose. The dose of carboplatin was determined
using the Calvert formula and, in most cases, glomerular filtration
rate (GFR) was obtained using radioisotope (51Cr-labelled
ethylenediaminetetraacetic acid (51CrEDTA)) measurement. Pre-medi-
cation with dexamethasone (8mg twice daily for 3 days starting the
day before docetaxel) was given, as well as prophylactic anti-emetics
with the chemotherapy. Erlotinib was taken orally, beginning 7 days
before the first dose of chemotherapy. On days of concomitant
administration, erlotinib was taken at least 1h before chemotherapy
(except when PK samples were being collected).
Treatment delays and dose reductions of docetaxel and
carboplatin were permitted based on predefined criteria. Occur-
rences of severe rash or diarrhoea not sufficiently controlled by
supportive treatment resulted in dose reduction of erlotinib by 25
or 50mgday
 1, followed by dose interruption if necessary.
The planned duration of treatment was six 3-week cycles of
chemotherapy. Erlotinib monotherapy was permitted after chemo-
therapy until disease progression or unacceptable toxicity. During
this period, the dose of erlotinib was increased from 50 to
150mgday
 1 by 25mgweek
 1 increments.
Determination of the MTD
The MTD was defined as the dose below which, during the first
cycle with erlotinib, DLTs were caused in 41/3 of patients. A DLT
was any of the following: grade 4 neutropaenia for 47 days; febrile
neutropaenia (absolute neutrophil count o1 10
9l
 1;t e m p e r a t u r e
X38.51C); grade 4 thrombocytopaenia (o10 10
9l
 1) associated
with bleeding or requiring platelet transfusion; grade 2 diarrhoea
lasting 448h despite loperamide treatment; any non-haematologic
toxicity Xgrade 3 (except tolerated rash and grade 3 self-limiting
or medically controllable toxicity); treatment delays exceeding 1
(erlotinib) or 2 weeks (chemotherapy), as a result of lack of
recovery from grade 2 toxicity.
Safety and tolerability
At baseline, patients underwent a physical examination, chest
X-ray, 12-lead electrocardiogram (ECG), GFR measurement (using
51CrEDTA or 24-h creatinine clearance), and standard blood tests
(full blood count and biochemical profile). Full blood count was
checked weekly. A physical examination, full blood count and
biochemistry were conducted before each cycle. ECOG PS was
evaluated at baseline and before each cycle.
Safety was assessed by the incidence and severity of adverse
events (AEs), using the National Cancer Institute Common
Toxicity Criteria (NCI-CTC) version 2.0 and changes in laboratory
values. Patients were assessed for AEs prior to each cycle, and were
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sencouraged to report any findings that occurred between hospital
visits. Pre-existing conditions that worsened during the course of
the study were also reported as AEs.
Pharmacokinetics
Pharmacokinetic analysis was carried out by MDS Pharma Services
(2350 Cohen Street, St Laurent, Quebec, Canada), using HPLC
combined with triple mass spectrometric detection. Pharmacoki-
netic parameters for erlotinib were evaluated in the first cycle with
erlotinib, in patients in cohort 1 only. Blood samples were collected
into lithium heparin tubes pre-dosing and at 0.5, 1, 2, 3, 4, 6, 8, 10
and 24h post-dosing on days  1, 1 and 7. Plasma samples,
prepared by centrifugation within 1h of collection, were stored
frozen at  701C until analysis.
The following PK parameters were evaluated for erlotinib:
maximum observed concentration (Cmax), time to peak concentra-
tion (Tmax) and area under the curve (AUC 0–24h). These
parameters were assessed on the day prior to chemotherapy, on
the day of chemotherapy and 6 days after chemotherapy.
Antitumour efficacy
At baseline, each patient underwent a pelvic examination and an
abdomino-pelvic computed tomography (CT) scan, and blood
levels of the ovarian tumour marker CA-125 were assessed.
Patients with palpable lesions had a pelvic examination before each
cycle. After cycles 3 and 6, abdomino-pelvic CT scans were
performed on patients who had (a) disease evident at baseline and
(b) a negative baseline scan with CA-125 evidence of disease
progression. CA-125 blood levels were measured before each
treatment cycle and during follow-up. Evaluation of tumour
response was based on the Response Evaluation Criteria in Solid
Tumours (RECIST) and on changes in CA-125 levels. Progression-
free survival was defined as time to progression or death from any
cause. Progressive disease was defined as either clinical evidence of
progressive disease based on either the RECIST Response Criteria
for Solid Tumours or elevated CA125 levels as defined as either (a)
an increase by twice the upper limit of normal for patients where
the Ca-125 normalises or is never elevelated, or (b) an increase by
twice the nadir value for patients with elevated pretreatment and
who do not normalise values after therapy (any elevated levels have
to be confirmed by repeat testing).
Statistical methods
In this study, a planned cohort size of 12 evaluable patients in each
dose escalation cohort was used, rather than the usual six. The main
reason for this was to reduce the risk of the MTD being established
on the basis of docetaxel/carboplatin toxicities alone. In addition,
the larger sample size provided greater power to detect any potential
effect of erlotinib on nadir neutrophil counts in cohort 1.
The cohort of the dose level to be taken forward to phase III was
planned to be expanded to 20 patients, to allow more experience
with the combination at this dose level.
For cohort 1, nadir neutrophil data and erlotinib PK were
analysed using repeated measures analysis of variance (ANOVA)
techniques. A log transformation was applied to the data before
analysis, in order to achieve approximate normality (this
transformation was based on the experience from other studies).
RESULTS
Patient characteristics and treatment
Forty-eight patients were registered at seven hospitals and
included 15, 13 and 20 patients in cohorts 1, 2a and 2b,
respectively. Three patients did not receive erlotinib and were
excluded from the study. In cohort 1, one patient had a severe
allergic reaction to docetaxel and another patient had complica-
tions due to a wound infection. The third patient (cohort 3)
withdrew consent. Baseline patient and disease characteristics are
summarised in Table 1.
Erlotinib duration ranged from 28 to 184 (cohort 1), 11 to 177
(cohort 2a) and 7 to 222 days (cohort 2b). The median erlotinib
doses were 47.5, 59.1 and 75.5mgday
 1 (cohorts 1, 2a and 2b,
Table 1 Baseline patient and disease characteristics
Characteristics Cohort 1 Cohort 2a Cohort 2b
Patients (n) 1 31 31 9
Median age (range) (years) 59.5 (47.9–68.3) 56.0 (32.4–65.7) 61.9 (49.1–68.7)
ECOG PS (n)
06 5 4
17 8 1 5
FIGO stage (n)
III 1 0 0
IIIa 0 1 0
IIIb 3 2 1
IIIc 6 7 15
IV 3 3 3
Histology (n)
Serous adenocarcinoma 11 10 17
Endometroid carcinoma 1 0 0
Adenocarcinoma 1 2 2
Other
a 010
Disease bulk (n)
None or microscopic 3 2 7
o2cm 6 4 2
X2cm 4 5 6
Not available 0 2 4
RECIST evaluable disease at baseline 6 6 11
aPrimary epithelial carcinoma of the ovary with hepatoid differentiation.
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srespectively). Treatment-related effects resulted in erlotinib dose
reduction/delay for some patients that is intolerable cutaneous
toxicity: n¼1, 2, 4; Xgrade 3 diarrhoea: n¼1, 1, 4; or other
reasons: n¼0, 4, 0 (cohorts 1, 2a and 2b, respectively). Erlotinib
treatment was stopped during the six cycles of combination
treatment for 1/13, 5/13 and 6/19 patients in cohorts 1, 2a and 2b,
respectively. The reasons for this cessation were cohort 2a: patient
refusal (n¼1), grade 3 diarrhoea (n¼2), other treatment-related
reason (n¼1) and not treatment related (n¼1); cohort 2b: refusal
(n¼2), diarrhoea (n¼1), rash (n¼2), and other treatment-
related reason (n¼1).
The majority of patients (32 of 44) received all six chemotherapy
cycles. Among the rest, 10 out of 12 patients received three cycles
or less. The main reasons for stopping treatment early were disease
progression/death from disease. Overall, 89% of cycles were
administered without any delay. Most of the delays were unrelated
to drug treatment (n¼14 cycles). Ten cycles were delayed due to
drug-related issues, and four of these were due to haematologic
toxicity (thrombocytopaenia, n¼3; neutropaenia, n¼1). Full
doses of carboplatin and docetaxel were administered in 96 and
94% of cycles, respectively.
Determination of MTD
In cohort 1 (initial erlotinib dose, 50mgday
 1), only one patient
had a DLT (grade 3 plantar–palmar erythrodysesthesia in cycle 2,
which was the first cycle involving erlotinib in this patient, as they
were part of the crossover phase of the study). In cohort 2a (initial
erlotinib dose, 100mgday
 1), 5 of 13 patients (38%) had at least
one DLT in the first cycle, namely persistent diarrhoea (two
patients); delayed erlotinib administration because of incomplete
recovery from grade 2 toxicity (four patients); and (all in one
patient) grade 3 vomiting, dehydration and rash, grade 4
oesophagitis and neutropaenic sepsis. Thus, erlotinib 100mgday
 1
with docetaxel and carboplatin exceeded the MTD. Patients were
subsequently recruited to cohort 2b.
In cohort 2b (initial erlotinib dose, 75mgday
 1), DLTs were
observed in 5 out of 19 (26%) patients in cycle 1. One patient had
grade 3 rash, whereas another had grade 3/4 febrile neutropaenia,
persistent diarrhoea, and grade 3 dysphagia, dehydration,
hyperglycaemia and dizziness. Three patients had erlotinib
administration delayed. Among these three, one also had several
grade 3 toxicities (dehydration, dysphagia, mucositis, abdominal
pain and throat pain) and another had grade 3 aesthenia and
dehydration.
Escalation of the dose of erlotinib (from 75 to 100mgday
 1) was
permitted for patients in cohort 2b following the satisfactory
completion of a cycle at 75mg. Eleven of 19 patients (58%) had a
dose escalation, that is, 4, 5, 1 and 1 patients starting in cycles 2, 3,
5 and 6, respectively. Twenty-three of 27 patients had their dose of
erlotinib increased to 150mgday
 1 after chemotherapy.
Safety and tolerability
All patients in the trial experienced at least one AE, the majority of
which were mild to moderate in severity. The most common grade
3/4 non-haematologic toxicities were diarrhoea, rash, fatigue and
dehydration (Table 2). As expected with docetaxel/carboplatin,
most patients experienced grade 3/4 haematologic toxicity
(Table 3). Neutropaenia was recorded in 85, 100 and 95% of
patients in cohorts 1, 2a and 2b, respectively.
There were no clinically significant changes in the results of
physical examinations, chest X-rays or ECGs. Most changes in
laboratory values were grade 1 or 2 and were not dose related.
There were very few grade 3/4 biochemical abnormalities (data not
shown) and these were not considered clinically important or
necessarily treatment related.
The data count from the crossover study conducted in cohort 1
indicated no statistically significant impact of erlotinib on nadir
neutrophil counts.
Pharmacokinetics
In the first cohort, seven patients received erlotinib in cycle 1, and
three in cycle 2. There were no clear differences in plasma Cmax,
Tmax or AUC(0–24h) values for erlotinib between samples taken
24h before or 6 days after chemotherapy, or on the same day as
chemotherapy (Table 4). Thus, the changes in Cmax, Tmax and
AUC(0–24h) over time (between days  1, 1 and 7) were not
statistically significant (P¼0.079, 0.410 and 0.882 respectively;
repeated measures ANOVA). The mean plasma concentration–
time curves for erlotinib alone and in combination with
chemotherapy (Figure 1) confirm that exposure to erlotinib is
unaffected by concomitant administration of docetaxel/carboplatin.
Antitumour efficacy
Twenty-four patients had measurable disease and were evaluable
for tumour response (data not shown). In total, five patients had a
complete response (CR), and seven patients had a partial response
(PR), giving an overall objective response rate (CR plus PR) was 12
out of 23 (52%).
Survival
Of the patients who completed chemotherapy, 17 have since
progressed and 23 have died. The median PFS for all patients was
Table 2 Most common non-haematologic AEs (grades 3 and 4) occurring in more than one patient in any cohort, during treatment with chemotherapy
Cohort 1 (n¼13) Cohort 2a (n¼13) Cohort 2b (n¼19)
AE Grade 3 n (%) Grade 4 n (%) Grade 3 n (%) Grade 4 n (%) Grade 3 n (%) Grade 4 n (%)
Diarrhoea 0 0 4 (31) 0 3 (16) 0
Fatigue 0 0 4 (31) 0 3 (16) 0
Rash/desquamation 0 0 3 (23) 0 2 (10) 0
Dehydration 0 0 1 (8) 0 3 (16) 0
Dysphagia 0 0 0 1 (8) 2 (10) 0
Nausea 0 0 3 (23) 0 0 0
Abdominal pain 0 0 1 (8) 0 1 (5) 0
Dermatology/skin other 1 (8) 0 0 0 1 (5) 0
Dizziness 0 0 1 (8) 0 1 (5) 0
Stomatitis/pharyngitis 0 0 0 0 2 (10) 0
Fainting 0 0 1 (8) 0 1 (5) 0
Vomiting 0 0 2 (15) 0 0 0
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s12.5 months (95% confidence interval (CI), 9.5–15.6 months) and
the median overall survival (OS) for all patients was 37.0 months
(95% CI, 27.3–46.7 months). The median follow-up for living
patients is 34 months (range, 25–45 months).
Outcomes among patients who received erlotinib
monotherapy after completion of chemotherapy
Of the 48 patients who started the study, 27 (56%) continued
erlotinib monotherapy after completion of chemotherapy. In 23 of
these patients, the dosage was escalated to 150mgday
 1,a s
planned. The median duration of treatment after chemotherapy
was 8.6 months (range 2.3–32.5 months). Twelve of the 27 patients
(44%) subsequently had their dose reduced or interrupted due to
toxicity (skin toxicity in 10 out of 12 patients). Nevertheless, apart
from alopoecia (33%), rash or desquamation (22%) and other skin
complaints (11%), the incidence of severe toxicity (grade 2 or
greater) was low.
Twenty-two patients (81%) stopped erlotinib because of
progressive disease and another three (11%) because of skin
toxicity. Two patients (7%) are continuing to receive erlotinib
without evidence of progression, both at a daily dose of less than
150mg (due to skin toxicity). The median PFS in patients receiving
erlotinib monotherapy was 14.8 months (95% CI): 12.6–17.1
months) and the median OS was 37.0 months (95% CI: 31.6–42.4
months).
DISCUSSION
This phase Ib study assessed the feasibility of combining erlotinib
with docetaxel and carboplatin as first-line therapy in patients with
advanced Mullerian cancers. The primary objective of this trial was
to determine the MTD of erlotinib with standard doses of
chemotherapy. In addition, this paper is the first report on the
PK of erlotinib combined with these agents.
The MTD of erlotinib was defined as 75mgday
 1 when
administered with docetaxel (75mgm
 2) and carboplatin (AUC
5) on day 1 of each 21-day cycle. The nine DLTs observed in 5 out
of 13 patients in cohort 2a (100mgday
 1 erlotinib) included
persistent diarrhoea and vomiting as well as dose cessation of
erlotinib. Interestingly, most patients (11/19, 58%) in cohort 2b
had their erlotinib dose escalated from 75 to 100mgday
 1 during
cycles 2–6, indicating that the higher dose could be reasonably
well tolerated when used in combination with chemotherapy, after
an initial lower dose.
The toxicity profile of erlotinib/docetaxel/carboplatin combined
was consistent with the known toxicities of the individual drugs.
All patients had at least one AE, but most of the toxicities were
mild to moderate in severity. The majority of patients had grade 3/
4 haematologic toxicities in response to chemotherapy, with
neutropaenia (93%) and leucopoenia (87%) being the most
common findings. Severe thrombocytopoenia (13%) and anaemia
(2%) occurred much less frequently. The present results, in
keeping with the key toxicities, are reported for first-line docetaxel/
carboplatin in patients with advanced ovarian carcinoma (Vasey
et al, 2004), that is 94, 9 and 11% grade 3/4 neutropaenia,
thrombocytopoenia and anaemia, respectively.
The other most common treatment-related grade 3/4 AEs in the
current study were diarrhoea, rash, febrile neutropaenia/infection
Table 3 Summary of grade 3 and 4 haematologic toxicities, during treatment with chemotherapy
Cohort 1 (n¼13) Cohort 2a (n¼13) Cohort 2b (n¼19)
Parameter Grade 3 n (%) Grade 4 n (%) Grade 3 n (%) Grade 4 n (%) Grade 3 n (%) Grade 4 n (%)
Leucopaenia 9 (69) 0 4 (31) 6 (46) 13 (68) 3 (16)
Thrombocytopaenia 1 (8) 0 2 (15) 3 (23) 0 0
Anaemia 0 0 1 (8) 0 0 0
RBC transfusions 3 6 6
Neutropaenia 2 (15) 9 (69) 1 (8) 12 (92) 2 (11) 16 (84)
Febrile neutropaenia 0 1 (8) 2 (15) 2 (15) 3 (16) 2 (11)
Infection/febrile neutropaenia 0 1 (8) 0 1 (8) 0 1 (5)
RBC transfusion threshold not mandated in protocol.
Table 4 PK parameters of erlotinib given alone or in combination with docetaxel and carboplatin (cohort 1)
Parameter Erlotinib alone (day  1)
Erlotinib in combination with
docetaxel/carboplatin (day 1) Erlotinib alone (day 7)
Cmax (ngml
–1) 922 (760–1119) 752 (624–906) 953 (738–1230)
Tmax (h) 2.4 (1.5–3.9) 3.8 (1.9–7.6) 2.9 (2.0–3.6)
AUC(0–24h) (nghml
 1) 10520 (7482–14791) 11041 (8241–14825) 11246 (7762–16293)
Data shown are geometric means (95% CIs) derived from the repeated measures analysis of variance, based on n¼10 patients with full profiles on each day (other three patients
did not have full profiles on each day).
1000
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Figure 1 Mean plasma concentration–time curves for erlotinib alone
and in combination with docetaxel and carboplatin for cohort 1.
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s(subsequent to severe chemotherapy-induced neutropaenia),
fatigue and dehydration. Diarrhoea is common with docetaxel/
carboplatin (Vasey et al, 2004) and with erlotinib (Shepherd et al,
2005). Similarly, fatigue is common to both chemotherapy and
erlotinib (Vasey et al, 2004; Shepherd et al, 2005). The rash
observed in the present trial resulted from the erlotinib therapy,
and has been reported in trials with erlotinib alone or in
combination with chemotherapy in various tumour types (Gordon
et al, 2005; Moore et al, 2005; Shepherd et al, 2005). Moreover,
evidence indicates that the presence and severity of rash is
correlated with survival in lung cancer (Perez-Soler et al, 2004),
pancreatic cancer (Moore et al, 2005) and ovarian cancer (Gordon
et al, 2005). As expected, AEs were more frequent with increasing
doses of erlotinib in this trial. However, there was no evidence of
cumulative toxicity as most patients completed the full six cycles of
planned treatment.
Various clinical trials have also demonstrated that combining
erlotinib with chemotherapy is feasible in a wide variety of
tumours. In previously reported phase I/Ib trials, the MTD of
erlotinib with cytotoxic agents ranged from 100mgday
 1 (with
capecitabine/docetaxel: Trigo et al, 2003; with capecitabine/
oxaliplatin: van Cutsem et al, 2003; with docetaxel: Mita et al,
2002) to 150mgday
 1 (with oxaliplatin/5-FU: Jones et al, 2003).
The MTD of erlotinib of 75mgday
 1 in the present trial is lower
than in trials with other combinations. This finding may be due to
the additive toxicities with docetaxel/carboplatin. Indeed, dose
escalation of erlotinib to 150mgday
 1 after chemotherapy
suggests that erlotinib is better tolerated as a single agent in this
patient setting.
Although preclinical and early clinical trials demonstrated
promising antitumour activity of erlotinib in combination with
chemotherapy, this benefit has not always been reflected in phase
III trials. For example, first-line treatment with erlotinib
(150mgday
 1) combined with standard platinum-based che-
motherapy did not improve survival in the overall population of
patients with advanced NSCLC; although never-smokers did
experience a significant survival benefit in a post-randomisation
analysis (Gatzemeier et al, 2004, 2005; Herbst et al, 2005). In
contrast, erlotinib with gemcitabine prolonged survival somewhat
in patients with previously untreated advanced pancreatic cancer
compared with gemcitabine alone (Moore et al, 2005).
Erlotinib PK parameters were similar when erlotinib was given
as a single agent or as part of the triple-drug combination,
suggesting that there was no interaction between the agents,
although the effect of erlotininb on the PK profiles of carboplatin
and docetaxel was not directly assessed. However, in the current
study, adding erlotinib to docetaxel/carboplatin resulted in an
objective response rate of 52%; lower than that reported for
docetaxel/carboplatin (59%) in our previously published phase III
randomised trial (Vasey et al, 2004). In clinical trials evaluating
first-line treatments for advanced ovarian carcinoma, the objective
response rates (i.e. CR plus PR) have been 59% (docetaxel/
carboplatin: Vasey et al, 2004), 59–68% (paclitaxel/carboplatin:
Neijt et al, 2000; du Bois et al, 2003; Vasey et al, 2004) and 61–81%
(paclitaxel/cisplatin: Neijt et al, 2000; du Bois et al, 2003). Possible
explanations for the relatively limited antitumour efficacy of the
triple-drug combination in this setting include the fact that the
patient population was unselected for EGFR expression (although
tissue samples were collected prior to study start for evaluation).
In addition, there were only a small number of patients (n¼45)
included this trial, and thus appropriate conclusions regarding the
efficacy of this regimen cannot be drawn.
In conclusion, 75mgday
 1 erlotinib was identified as the MTD
in combination with standard doses of docetaxel (75mgm
 2) and
carboplatin (AUC 5) on day 1 of 3-week cycles in patients with
advanced, previously untreated ovarian cancer. Significant DLTs
include rash and diarrhoea, which limit the usefulness of this
combination regimen. Maintenance erlotinib following six cycles
of combination chemotherapy is also associated with cutaneous
toxicity, which can limit the dose and duration of treatment,
although monotherapy does permit a higher dose to be given.
The potential benefit of this maintenance approach can only be
addressed in a randomised trial. Under the auspices of the
European Organisation for Research and Treatment of Cancer
(EORTC), this is now being examined in a trial in which
responding patients are randomised to erlotinib or control after
completing platinum-based induction treatment. A parallel trans-
lational component to this international study will evaluate the
possibility that patients most likely to derive benefit from erlotinib
can be predicted by molecular tumour analysis. This phenomenon,
in a similar manner to that seen in NSCLC, has been observed in a
blinded molecular analysis of a Gynecologic Oncology Group
(GOG) phase II trial in ovarian cancer with another EGFR
inhibitor, gefitinib (Schilder et al, 2005). Results of the EORTC
erlotinib trial are expected in 2009.
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